PATENT CLAIM ANALYSIS

Application Number: 16173114
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["424", "136100"]

Abstract:
Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

Claim (Index 79):
A multispecific antigen binding protein which promotes the specific lysis of target cells expressing an antigen of interest, which antigen is specifically bound by a therapeutic antibody or therapeutic antigen-binding antibody fragment, wherein said multispecific antigen binding protein comprises:\n (i) a first antigen binding domain (ABD) which monovalently binds to a human NKp46 polypeptide having the amino acid sequence set forth in SEQ ID NO:1, (ii) a second ABD which comprises a therapeutic antibody or a therapeutic antigen-binding antibody fragment which binds to said antigen of interest expressed by said target cells, and (iii) a CD16A binding polypeptide, wherein:\n (1) said NKp46-binding ABD comprises a Fab or comprises a variable heavy (V H ) domain and a variable light (V L ) domain separated by a linker (\u201cscFv\u201d); \n (2) said antigen-binding ABD which comprises said therapeutic antibody or therapeutic antigen-binding antibody fragment is monovalent or bivalent; \n (3) said CD16A binding polypeptide comprises a human Fc domain polypeptide which binds CD16A; \n (4) said multispecific antigen binding protein binds to the NKp46 polypeptide monovalently; \n (5) said multispecific antigen binding protein when administered to a subject directs NKp46-expressing natural killer (NK) cells and CD16A-expressing NK cells to lyse target cells expressing the antigen of interest by a combination of NKp46-mediated signaling and CD16A-mediated antibody-dependent cell-mediated cytotoxicity (\u201cADCC\u201d); \n (6) said dimeric Fc domain interposes said first ABD and said second ABD; and \n (7) said first and second ABD are each connected to said dimeric Fc domain, and one or both of said first and second ABD are connected to the dimeric Fc domain via a flexible polypeptide linker.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 97.0
- Lexical Diversity: 1.31429
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15190337', '15321650', '14691509', '16041309', '11921123']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7896676665511339
- 35 USC 102 Novelty (BERT): 0.7209662296295422
- Combined Prediction Score: 0.7827975228589747
- Mean Citation Score: 535.968584
- Max Citation Score: 918.7742
- Similarity Product: 753.5013518715143

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test